NAPLES, FL, May 5, 2022 /CNW/ – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it will host a…
Read More
NAPLES, Fla., May 3, 2022 /CNW/ – Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that its Board of…
Read More
NAPLES, Fla., April 6, 2022 /CNW/ – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive…
Read More
NAPLES, Fla., March 31, 2022 /CNW/ – Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today reported its financial results for the full…
Read More
NAPLES, Fla., March 29, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health medicines, announces the filing of a provisional patent application based on…
Read More
Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders NAPLES, Fla., March 15, 2022 /CNW/ – Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or…
Read More
NAPLES, Fla., March 3, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive Officer of…
Read More
Robust Portfolio of Psychedelic-Inspired Molecules Positions Enveric to Achieve Global Patent Protection to potentially Cover Millions of Novel Pharmaceutical Candidates NAPLES, Fla., March 1, 2022 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),…
Read More
Clinical trial aim is to include the identification and characterization of the Cancer Related Distress symptoms most responsive to psychedelic-associated therapy NAPLES, Fla., Feb. 17, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB)(“Enveric” or…
Read More
NAPLES, Fla., Feb. 15, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health and oncology treatments, today announced the closing of its…
Read More
